* Vaxcyte Inc PCVX.OQ PCVX.O is expected to show no
change in
quarterly revenue when it reports results on February 27 for
the period ending December 31 2023
*
* LSEG's mean analyst estimate for Vaxcyte Inc is for a
loss of
$1.07 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Vaxcyte Inc
is
$76.00, below its last closing price of $76.87.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Sep. 30 2023 -0.84 -0.84 -0.91 Missed -8.7
Jun. 30 2023 -0.75 -0.74 -0.70 Beat 6
Mar. 31 2023 -0.84 -0.83 -0.70 Beat 15.2
Dec. 31 2022 -0.98 -0.93 -1.02 Missed -9.7
Sep. -0.84 -0.84 -0.93 Missed -11.2
30 2022
Jun. 30 2022 -0.69 -0.69 -0.80 Missed -15.9
Mar. 31 2022 -0.64 -0.63 -0.68 Missed -8.5
Dec. 31 2021 -0.52 -0.56 -0.55 Beat 1.8
This summary was machine generated February 24 at 00:00 GMT.
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)